关于向控股子公司焦作健风提供委托贷款的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、委托贷款概述 健康元药业集团 委托贷款进展公告 证券代码：600380 证券简称：健康元 公告编号：临 2025-052 健康元药业集团股份有限公司 2025 年 2 月 11 日，本公司通过招商银行向焦作健风发放委托贷款人民币 1,000 万元，其中 500 万元用于支付项目相关的构建费用，500 万元用于公司流动资金周 转。截至 2025 年 2 月 11 日，本公司在董事会审议通过的人民币 10,000 万元委托贷 款额度内，已向焦作健风发放委托贷款合计人民币 8,500 万元，其中 6,500 万元用于 支付项目相关的构建费用，2,000 万元用于公司流动资金周转，详见《健康元药业集 团股份有限公司关于向控股子公司焦作健风提供委托贷款的进展公告》（临 2025-009）。 2025 年 6 月 24 日，本公司通过招商银行再次向焦作健风发放委托贷款人民币 1,500 万元，全部用于支付项目相关的构建费用。截至本公告披露日 ...

Group 1 - China State Construction won multiple major projects with a total amount of 21.53 billion yuan, accounting for 1.0% of the audited revenue for 2024 [1] - Zhongtai Chemical's subsidiary has fully launched a methanol upgrading demonstration project, which will further reduce production costs [1] - Wide Special Materials expects a net profit increase of approximately 367.51% year-on-year for the first half of 2025, driven by improved demand and internal optimization [1][2] Group 2 - Longdi Group plans to exercise its preferential subscription rights to participate in the convertible bond issuance of its associate company, Yongqi Electronics, with an investment of no more than 89.249 million yuan [3] - Dayou Energy's subsidiary Mengjin Coal Mine has resumed production after a 38-day suspension due to an accident, with an annual capacity of 1.2 million tons [5] - Shanying International plans to repurchase shares worth between 500 million and 1 billion yuan, with a maximum repurchase price of 2.50 yuan per share [7] Group 3 - Huatai Securities has been approved to issue up to 10 billion yuan in technology innovation bonds to support investment in the technology innovation sector [9] - Weixin Kang's cooperative product, an injectable multivitamin, has passed the consistency evaluation, enhancing its market potential [10] - Jinpu Titanium's controlling shareholder will have 35 million shares auctioned, accounting for 3.55% of the company's total share capital [11] Group 4 - China Pharmaceutical plans to waive its preferential purchase rights for a 24% stake in Chongqing Medical Health Industry Co., with a base transfer price of 2.206 billion yuan [12] - Beijia Clean plans to reduce its shareholding by 1.99% due to funding needs [13] - Anpelon has obtained a design patent for a brake sensor, enhancing its technological capabilities [14] Group 5 - Zhongyue Holdings' subsidiary has received approval for a clinical trial application for a new drug, indicating progress in its pharmaceutical development [14] - Lijun Group's YJH-012 injection has been approved for clinical trials, showcasing its potential in treating gout [16] - Yageer has sold financial assets totaling 4.176 billion yuan, representing 10.13% of its audited net assets for 2024 [15] Group 6 - Tailing Micro expects a net profit increase of approximately 267% year-on-year for the first half of 2025, driven by customer demand and product sales [19] - Baotai plans to invest 287 million yuan to acquire a 51% stake in Shaanxi Wanhao Titanium Technology Co., enhancing its production capabilities [21] - Laime Pharmaceutical has received a drug registration certificate for azithromycin granules, expanding its product portfolio [23] Group 7 - KQ Bio has received approval for a new veterinary vaccine, marking a significant advancement in its product offerings [25] - Robotech signed a contract worth approximately 17.1 million euros, representing over 12.82% of its audited revenue for 2024 [26] - Alloy Investment is planning a control change, leading to a temporary suspension of its stock [27] Group 8 - Huabang Health's subsidiary has received approval for two dermatological drugs, indicating growth in its pharmaceutical pipeline [28] - Lingxiao Pump Industry plans to invest 60 million yuan in wealth management products, optimizing its financial strategy [29] - Jinzhong Technology has won projects totaling 113 million yuan, accounting for 6.39% of its expected revenue for 2024 [31] Group 9 - Yifan Pharmaceutical's subsidiary has received approval for a clinical trial of a growth hormone injection, indicating progress in its research and development [32] - Guiguan Electric plans to invest 395 million yuan in a photovoltaic project, reflecting its commitment to renewable energy [33] - Rili Technology intends to repurchase shares worth between 10 million and 20 million yuan, supporting its stock performance [34] Group 10 - Xingye Securities' chairman has resigned, leading to a change in leadership [35] - Jinko Solar has achieved third-party certification for its high-efficiency solar cells, setting a new industry record [37] - Changan Automobile's controlling shareholder has changed its name, reflecting a rebranding effort [38]

证券代码：600380 证券简称：健康元 公告编号：临 2025-051 健康元药业集团股份有限公司 关于获得药物临床试验批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，健康元药业集团股份有限公司（以下简称：本公司）控股子公司丽珠医 药集团股份有限公司（以下简称：丽珠集团）收到国家药品监督管理局核准签发的 《药物临床试验批准通知书》（通知书编号：2025LP01629），批准 YJH-012 注射 液开展临床试验。现将有关详情公告如下： 健康元药业集团 关于获得药物临床试验批准通知书的公告 申请人：丽珠医药集团股份有限公司 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，2025 年 4 月 14 日受理的 YJH-012 注射液临床试验申请符合药品注册的有关要求，同意 本品开展痛风适应症临床试验。 二、药品研发及相关情况 YJH-012 注射液是丽珠集团与佑嘉（杭州）生物医药科技有限公司联合开发的 新型 siRNA 药物。区别于传统药物抑制酶活性以阻断尿酸合成，YJH-012 注射液 采 ...

Core Viewpoint - The company announced that its subsidiary, Lizhu Group, received approval from the National Medical Products Administration for clinical trials of YJH-12 injection, a new siRNA drug for gout [1] Group 1: Company Developments - Lizhu Group, a subsidiary of the company, is collaborating with Youjia (Hangzhou) Biopharmaceutical Technology Co., Ltd. to develop the YJH-12 injection [1] - The total research and development expenses incurred for YJH-12 injection amount to approximately RMB 25.7386 million [1] - There are currently no similar small nucleic acid products approved for the same indication in the domestic market [1]

Group 1 - The company has received approval from the National Medical Products Administration for clinical trials of the drug JKN2301, which is a dry suspension intended for children aged 2 to 12 years with uncomplicated influenza [1][2] - JKN2301 is developed from the patented compound Marapacisavir and aims to meet the clinical needs in the treatment of influenza in children, allowing for flexible dosage adjustments based on weight [1][2] - The total research and development expenses incurred by the company for JKN2301 amount to approximately RMB 6.9453 million [2] Group 2 - Influenza poses a global public health issue, with seasonal outbreaks leading to significant health impacts; the estimated domestic terminal sales of antiviral drugs for influenza in 2024 is around RMB 4.7 billion [2]

健康元药业集团 关于获得临床试验批准通知书的公告 证券代码：600380 证券简称：健康元 公告编号：临 2025-050 健康元药业集团股份有限公司 关于获得临床试验批准通知书的公告 申请人：健康元药业集团股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，健康元药业集团股份有限公司（以下简称：本公司）收到国家药品监督管理局 （以下简称：国家药监局）核准签发的《药物临床试验批准通知书》，批准公司的 JKN2301 干混悬剂开展临床试验。现将有关详情公告如下： 一、批准通知书的主要内容 药物名称：JKN2301 干混悬剂 剂型：干混悬剂 申请事项：临床试验申请 注册分类：化学药品 1 类 审批结论：经审查，2025 年 3 月 26 日受理的 JKN2301 干混悬剂临床试验申请符合药 品注册的有关要求，同意本品开展临床试验。申请的适应症：本品适用于 2 至 12 周岁以 下单纯性甲型和乙型流感儿童患者。 二、药品研发及相关情况 本次获批临床试验的 JKN2301 干混悬剂，是以专利化合物玛帕西沙韦开发的创新药 ...

医药生物行业资金流入榜 | 代码 | 简称 | 今日涨跌幅（%） | 今日换手率（%） | 主力资金流量（万元） | | --- | --- | --- | --- | --- | | 002173 | 创新医疗 | 10.04 | 31.78 | 58181.79 | | 600276 | 恒瑞医药 | -0.44 | 0.59 | 8207.12 | | 002550 | 千红制药 | -1.05 | 11.19 | 7525.42 | | 002826 | 易明医药 | 1.91 | 24.11 | 6926.24 | | 600380 | 健康元 | -0.63 | 0.80 | 3477.83 | | 002793 | 罗欣药业 | -1.05 | 3.22 | 2826.06 | | 688166 | 博瑞医药 | -0.45 | 2.17 | 2795.76 | | 688235 | 百济神州 | -0.39 | 1.51 | 2696.74 | | 688117 | 圣诺生物 | 1.47 | 6.91 | 2654.77 | | 688271 | 联影医疗 | 0.15 | 0.34 | 2 ...

健康元（600380）公告，公司收到国家药监局核准签发的《药物临床试验批准通知书》，批准JKN2301 干混悬剂开展临床试验。该药品适用于2至12岁以下单纯性甲型和乙型流感儿童患者，是以专利化合物 玛帕西沙韦开发的创新药，可根据儿童体重灵活调整剂量，提高儿童用药依从性。 ...

Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" (maintained) [1] Core Insights - The flu virus is a highly pathogenic pathogen, and the development of new mechanism drugs is imperative [4] - The flu is a common respiratory infectious disease with a high transmission rate, affecting approximately 1 billion people globally each year, with 300,000 to 500,000 severe cases and 290,000 to 650,000 deaths due to flu-related respiratory diseases [4][15] - The domestic flu drug market has exceeded 10 billion yuan, with Oseltamivir holding over 80% market share, while Baloxavir has seen rapid growth from 0.07 billion yuan in 2022 to 0.63 billion yuan in 2023 [6][36] Summary by Sections 1. Flu Virus and Drug Development - The flu virus is categorized into four types: A, B, C, and D, with A and B being the primary types responsible for widespread outbreaks [17][20] - The main drug targets during flu infection include the surface proteins Hemagglutinin (HA) and Neuraminidase (NA), with RNA polymerase inhibitors emerging as the mainstream research target in antiviral drug development [5][26] 2. Market Dynamics - The flu drug market in China is projected to grow significantly, with new domestic drugs expected to launch in 2025, enhancing sales potential and company performance [7][36] - The sales of flu drugs in the domestic market reached 11.405 billion yuan in 2023, with Oseltamivir accounting for 86.48% of the market share [36] 3. Investment Recommendations - Recommended stocks include Jichuan Pharmaceutical and Health元, with beneficiaries including Zhongsheng Pharmaceutical and Xiansheng Pharmaceutical [7]

Core Points - The company held its 2024 annual shareholders' meeting on June 6, 2025, with a shareholder attendance rate of 51.11% [1] - The cash dividend proposal received overwhelming support, with 99.91% approval from shareholders holding more than 5% of the shares [1] Summary by Categories Profit Distribution - The profit distribution plan for 2024 was approved with a support rate of 97.9% from minority investors, and 98.39% from shareholders with a market value below 500,000 [2] Financing Guarantees - The proposal for credit financing and providing guarantees for subsidiaries was approved with a 97.66% approval rate, although there was significant disagreement among minority investors, with only 44.38% in favor [2] Audit Reappointment - The reappointment of Deloitte Touche Tohmatsu as the auditing firm for 2025 was approved with a 99.74% support rate [2] Key Data - A total of 935 million shares were voted, representing 51.11% of the company's total share capital [3] Non-Operating Fund Usage - The special report on non-operating fund usage was approved with a 99.87% support rate [4] Subsidiary Loan Guarantees - The loan guarantee proposal for the subsidiary Jinguang Electric was supported by 99.83% of the votes [5] Compliance and Legality - The meeting procedures complied with the Company Law and the company's articles of association, presided over by director Lin Nanqi, with all board members and supervisors present [6] Impact - The resolutions clarified the company's financial distribution for 2024 and the financing guarantee framework for 2025, enhancing risk control for subsidiaries and maintaining audit stability, signaling robust operations to investors. Minority investors significantly benefited from the dividend plan but showed low participation in the financing guarantee matters [7]